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ABSTRACT
Introduction Seasonal malaria chemoprevention (SMC), 
with sulphadoxine–pyrimethamine plus amodiaquine 
(SP+AQ) is effective but does not provide complete 
protection against clinical malaria. The RTS,S/AS01
E 
malaria vaccine provides a high level of protection 
shortly after vaccination, but this wanes rapidly. Such a 
vaccine could be an alternative or additive to SMC. This 
trial aims to determine whether seasonal vaccination 
with RTS,S/AS01
E vaccine could be an alternative to 
SMC and whether a combination of the two interventions 
would provide added benefits.
Methods and analysis This is an individually 
randomised, double- blind, placebo- controlled trial. 5920 
children aged 5–17 months were enrolled in April 2017 
in Mali and Burkina Faso. Children in group 1 received 
three priming doses of RTS,S/AS01
E vaccine before 
the start of the 2017 malaria transmission season and 
a booster dose at the beginning of two subsequent 
transmission seasons. In addition, they received SMC 
SP+AQ placebo on four occasions each year. Children in 
group 2 received three doses of rabies vaccine in year 
1 and hepatitis A vaccine in years 2 and 3 together with 
four cycles of SMC SP+AQ each year. Children in group 
3 received RTS,S/AS01
E vaccine and four courses of 
SMC SP+AQ. Incidence of clinical malaria is determined 
by case detection at health facilities. Weekly active 
surveillance for malaria is undertaken in a randomly 
selected subset of children. The prevalence of malaria 
is measured in surveys at the end of each transmission 
season. The primary endpoint is the incidence of clinical 
malaria confirmed by a positive blood film with a 
minimum parasite density of 5000 /µL. Primary analysis 
will be by modified intention to treat defined as children 
who have received the first dose of the malaria or 
control vaccine.
Ethics and dissemination The protocol was approved 
by the national ethics committees of Mali and 
Burkina Faso and the London School of Hygiene and 
Tropical Medicine. The results will be presented to all 
stakeholders and published in open access journals.
Trial registration number NCT03143218; Pre-results
INTRODUCTION
The RTS,S/AS01E malaria vaccine is a 
recombinant protein vaccine that contains a 
component of the circumsporozoite protein 
of Plasmodium falciparum fused to hepatitis 
B surface antigen (HBsAg), co- expressed in 
Strengths and limitations of this study
 ► One major strength of this trial is that it is exploring 
a novel approach of seasonal vaccination to malaria 
control in an area where the burden of malaria re-
mains very high despite a high coverage of currently 
recommended interventions.
 ► The study is adequately powered to test the non- 
inferiority hypotheses, which requires a large sam-
ple size.
 ► A third strength of the trial is that the clinical impact 
of the two interventions is supported by laboratory 
studies, which will measure the impact of seasonal 
malaria chemoprevention on drug resistance and of 
RTS,S/AS01
E on potential vaccine escape parasites.
 ► Despite establishment of an intensive surveillance 
system, some episodes of malaria and some serious 
adverse events may be missed, but because the trial 
is individually randomised these should be distribut-
ed equally among study groups.
 ► To apply the trial results to areas where the seasonal 
malaria transmission duration and pattern is differ-
ent, modelling may be needed.
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yeast together with a free HBsAg (S) to form a virus- like 
particle (RTS,S). It is given with the powerful adjuvant 
AS01E.
1 A phase 3 trial of RTS,S/AS01E conducted in 
15 439 children in 7 countries in Africa showed that three 
doses of RTS,S/AS01E given at monthly intervals, followed 
by a fourth dose 18 months later, gave 36.5% [95% CI 
31% to 41%] protection against clinical attacks of malaria 
in children aged 5–17 months who were followed for 48 
months.2 RTS,S/AS01E provides a high level of protection 
during the first 3 months after vaccination,3 estimated 
to be 68% in the phase 3 trial.4 The main safety issues 
related to administration of RTS,S/AS01E detected in the 
phase 3 trial were (1) an unexplained, statistically signifi-
cant, increase in cases of meningitis observed in children 
given the vaccine at the age of 5–17 months, (2) a possible 
increase in the proportion of severe cases of malaria that 
were classified as cerebral malaria and (3) a gender imbal-
ance in the small number of deaths recorded during the 
trial.5
Seasonal malaria chemoprevention (SMC) involves 
monthly administration of a full therapeutic dose of 
an antimalarial drug or drug combination to chil-
dren on three or four occasions during the period of 
highest risk of malaria infection. Studies undertaken in 
several countries in West Africa have shown that SMC 
with a combination of sulphadoxine/pyrimethamine 
(SP) and amodiaquine (AQ) (SP+AQ) is highly effec-
tive in reducing the incidence of severe and uncom-
plicated malaria in areas where the transmission of 
malaria is markedly seasonal.6–8 SMC with SP+AQ is 
very safe.9 Many countries in the Sahel and sub- Sahel 
region of West Africa have now incorporated SMC into 
their national malaria control programme achieving 
high levels of coverage10 but malaria continues to be a 
major cause of mortality and morbidity in these coun-
tries and additional control tools are needed. Adding 
azithromycin to the antimalarial drugs used for SMC 
did not reduce hospital admissions or deaths from non- 
traumatic causes.11 Thus, determining whether adding 
RTS,S/AS01E would provide valuable additional protec-
tion is important. The primary objectives of the trial are 
to determine (1) whether seasonal vaccination following 
priming with the RTS,S/AS01E malaria vaccine is non- 
inferior in preventing malaria to SMC with SP+AQ in 
children living in the areas of the Sahel and sub- Sahel 
region of West Africa where malaria transmission is 
highly seasonal and (2) whether RTS,S/AS01E can 
provide additional, useful and cost- effective protection 
against malaria if given together with SMC in areas with 
high seasonal malaria transmission.
METHODS
This is an individually randomised, double- blind, 
placebo- controlled trial with three groups. The trial will 
be conducted and reported according to Consolidated 
Standards of Reporting Trials guidelines.12
Study setting
The trial is being conducted in Houndé district, Burkina 
Faso, and in Bougouni district, Mali (figure 1). Malaria, 
due, predominantly, to P. falciparum, is highly seasonal 
in both districts. The prevalence of P. falciparum malaria 
in school- age children in December 2016 was 53% in 
Bougouni and 50% in Houndé.11 The main malaria 
vector in both study areas is Anopheles gambiae ss. In 2016, 
a high proportion of children slept under an insecticide- 
treated bednet (ITN) in Bougouni (95%) but the 
percentage was slightly lower in Houndé (79.9%). The 
first- line treatment for malaria in the public health system 
in both districts is artemether–lumefantrine. The inci-
dence of parasite confirmed malaria was 1068 per 1000 
child years at risk during the transmission season among 
3–59- month- old children who were allocated to the SMC 
group in a trial conducted in Bougouni and Houndé 
districts in 2014–2016.11 Malaria is seasonal, with 79.6% 
of annual cases occurring over 5 months of the year from 
July to November in Bougouni and 81.0% between July 
and November in Houndé.
Study population
All households within the study areas with children 
5–17 months of age on 1 April 2017 were enumerated 
in February–March 2017 and children were screened for 
their eligibility to enter the trial. A child was considered 
eligible if (a) the child was a permanent resident of the 
study area and likely to remain a resident for the duration 
of the trial or (b) the child was 5–17 months of age on 1 
April 2017. A child was deemed to be ineligible if (a) the 
child was a transient resident; (b) the age of the child was 
outside the stipulated range; (c) the child had a history 
of an adverse reaction to SP or AQ; (d) the child had a 
serious underlying illness (self- reported or obtained from 
health records), including known HIV infection, unless 
Figure 1 Study districts in Mali and Burkina Faso.
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this was well controlled by treatment, or severe malnutri-
tion (weight for age or mid arm circumference Z scores 
<3 SD); (e) the child was known to have an immune 
deficiency disease or was receiving an immunosuppres-
sive drug; (f) the child had previously received a malaria 
vaccine or (g) the child was enrolled in another malaria 
intervention trial. Written, informed consent (online 
supplemental file 1) was obtained by study staff from their 
caretakers of eligible children prior to their inclusion in 
the trial.
Each eligible child was assigned a unique census identi-
fication number (ID), and their demographic data (date 
of birth and/or age, and gender), use of ITNs and history 
of receiving SMC during the last transmission season were 
collected. The census data were updated in April/May 
2018 and 2019 prior to the administration of the booster 
doses of vaccine.
The study started on 1 February 2017 and is expected to 
be completed on 30 June 2020 (figure 2).
Patient and public involvement
No patients are involved in this trial. Healthy children 
were enrolled with the consent of their caretakers. 
Caretakers were not involved in the development of the 
research question or study design.
Randomisation
Eligible children who were consented soon after the 
census were allocated randomly to one of the three study 
groups (table 1). The randomisation list was prepared 
using permuted blocks after sorting the list of eligible 
children by age, gender, area of residence and prior 
receipt of SMC, to ensure these characteristics would 
be balanced between the three groups. An independent 
information technology consultant loaded the randomis-
ation list on four tablet computers and handed over two 
tablet computers each to the chief pharmacist in Mali and 
Burkina Faso. The chief pharmacists used these tablet 
computers to scan the QR code containing the child’s 
name and study ID printed on the ID cards of children to 
find out the vaccine allocated to each child. These tablet 
computers were locked in the vaccine room and were 
accessible to the chief pharmacists only.
Interventions
RTS,S/AS01E vaccine: three doses of RTS,S/AS01E were given 
to children allocated to the RTS,S or RTS,S+SMC groups at 
Figure 2 Study design.
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approximately monthly intervals (window: 3–8 weeks) in 
April–June 2017 followed by a fourth and fifth dose given in 
June 2018 and June 2019 prior to the malaria transmission 
seasons.
Control vaccines: rabies vaccine Rabipur®, produced by 
GlaxoSmithKline (GSK), was used as the control vaccine for 
the primary series of vaccinations during the dry season of 
2017 for those allocated to the SMC alone group. Hepatitis 
A vaccine (Havrix), a licensed inactivated hepatitis A vaccine 
produced by GSK, was used for the booster dose in years 2 
and 3.
SMC: four courses of SMC with SP+AQ were given at 
monthly intervals during the malaria transmission season 
in line with WHO’s recommendation and national policy. A 
course of SMC for a child over the age of 1 year comprises 
a single treatment of SP (500 mg sulphadoxine/25 mg pyri-
methamine) and AQ 150 mg on day 1 and AQ 150mg on 
days 2 and 3. Infants receive half of these doses. Children in 
the RTS,S alone group received a matching SP+AQ placebo. 
Dispersible forms of SP and AQ and matching placebo were 
obtained from Guilin Pharmaceuticals, Shanghai, a Good 
Manufacturing Practice certified supplier. All doses of SMC 
were given under observation.
Implementation of the interventions
Vaccines: syringes containing RTS,S/AS01E or the control 
vaccine were prepared by the chief pharmacist who took 
no other part in the trial. Loading of syringes with vaccines 
and masking with tape to blind the person administering the 
vaccine was done by a member of the study staff who also 
took no further part in the trial. Vaccines were administered 
by study health staff trained to give vaccines.
Vaccination was undertaken in fixed or temporary centres 
established near study health centres or hospitals. The fami-
lies of children scheduled for vaccination on a particular day 
were notified the day before this was due to take place and 
asked to bring their child to the vaccination centre on that 
day. In the case of families who lived a long distance from a 
vaccination centre, project transport was provided to bring 
the children and caretakers to the vaccination centre and 
to take them home. Children were retained at the vaccina-
tion centre for at least 30 min after vaccination to ensure that 
there were no immediate adverse events. Home visits were 
made to the families of children who missed vaccination on 
the designated day and their caretakers were asked if they 
would still like their child to receive vaccination (or SMC). 
If they agreed, they were asked to bring their children to the 
vaccination/drug administration centre. Some children were 
unable to attend for vaccination at the time that this took 
place in their community because their family had travelled 
or due to an acute illness. A protocol amendment, approved 
by the data and safety monitoring board, allowed these chil-
dren to receive the booster vaccination in 2018 and in 2019 
if they presented for SMC administration later in the malaria 
transmission season.
SMC: SMC drugs were pre- packed by a pharmacist who 
took no further part in the trial, in re- sealable envelopes 
bearing the child’s unique number and containing tablets 
for the four cycles of treatment appropriate for the child’s 
age. Each dose of SMC or placebo was administered by 
trained project staff at a central point in the study village. 
Study children were given an identity card containing their 
photograph, study identity number and date of birth. At the 
time of vaccination and/or SMC administration, a child’s 
photo ID card was scanned to ensure that the child was 
given the allocated intervention. The Ministry of Health 
(MoH) introduced administration of SMC in the study 
areas in Mali and Burkina Faso in 2018. A member of the 
study team accompanied the MoH team to prevent the risk 
of study children receiving SMC again from the routine 
system.
ITNs: all study children were given an ITN at enrolment 
in 2017 before the malaria transmission season.
Study outcomes
The primary trial outcome is clinical malaria, defined 
as an episode of illness characterised by fever (tempera-
ture ≥37.5°C), or a history of fever within the previous 
48 hours, that is severe enough to require treatment at 
a health centre or by a community health worker and 
which is accompanied by a positive blood film with a para-
site density of 5000 /µL or more.
Secondary outcomes include the following:
1. Blood slide or rapid diagnostic test (RDT): positive ma-
laria is defined as a clinical episode of an uncomplicat-
ed febrile illness (temperature ≥37.5°C), or a history 
of fever within the previous 48 hours, with a positive 
blood film (any level of asexual parasitemia) or a pos-
itive RDT.
2. Hospital admissions with malaria, including cases of se-
vere malaria which meet WHO criteria for a diagnosis 
of severe malaria.
Table 1 Study groups and the interventions that they 
received
Group 1 Group 2 Group 3
RTS,S/AS01E 
alone SMC alone
SMC+RTS,S/
AS01E
Year 1
  April–June RTS,S/AS01E×3 Rabies 
vaccine×3
RTS,S/AS01E×3
  July–Oct SMC placebo*×4 SMC*×4 SMC*×4
Year 2
  June RTS,S/AS01E×1 Hepatitis A 
vaccine×1
RTS,S/AS01E×1
  July–Oct SMC placebo*×4 SMC*×4 SMC*×4
Year 3
  June RTS,S/AS01E×1 Hepatitis A 
vaccine×1
RTS,S/AS01E×1
  July–Oct SMC placebo*×4 SMC*×4 SMC*×4
*SMC or placebo will be given at monthly intervals on four occasions 
during the malaria transmission season.
SMC, seasonal malaria chemoprevention.
 o
n
 Septem
ber 16, 2020 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-035433 on 15 September 2020. Downloaded from 
5Chandramohan D, et al. BMJ Open 2020;10:e035433. doi:10.1136/bmjopen-2019-035433
Open access
3. Malaria parasitaemia (symptomatic or asymptomatic) 
in a subset of randomly selected children seen during 
home visits.
4. Malaria parasitaemia (asymptomatic or symptomatic), 
moderate or severe anaemia, and malnutrition at the 
end of the malaria transmission season.
5. Serious adverse events (SAEs), including any deaths, 
with special reference to meningitis, cerebral malaria 
or immune deficiency illnesses.
6. Anti- circumsporozoite protein (CSP) concentrations 
obtained after priming and after each booster dose, 
determined in a sub- sample of children.
7. The presence of molecular markers of resistance to SP 
and AQ in parasite positive samples collected at the 
last cross- sectional survey.
8. The match of polymorphisms in the P. falciparum cir-
cumsporozite (csp) gene of parasite isolates obtained 
from children with clinical episodes of malaria to the 
genetic structure of the strain of parasite used to devel-
op the RTS,S/AS01E vaccine.
Sample size
Based on the sample size calculations described below, 
the trial aimed to recruit approximately 3000 children in 
Burkina Faso and 3000 in Mali (total 6000) who would be 
followed for three years. A low dropout rate of around 5 
% per year (15% overall) was anticipated based on find-
ings from a previous trial conducted in the same study 
areas.12 Based on the results of a blinded interim analysis 
of an SMC+azithromycin study,12 it was assumed that the 
incidence of clinical malaria confirmed by blood slide 
would be 300 cases per 1000 children over a calendar year 
in the SMC alone group. Results obtained over a period 
of three years of observation in the two study sites will be 
combined for the comparison of the primary endpoint 
but secondary analyses will evaluate impact at each study 
site separately. The study is powered to (1) assess the statis-
tical evidence against the null hypothesis of no difference 
between the combined group and either the SMC alone 
or RTS,S alone group and (2) estimate the efficacy of 
the combined group relative to the single intervention 
groups with a relatively high degree of precision. This 
latter aspect is important because if the combined inter-
vention is to be used in practice, it is necessary to show 
that adding RTS,S/AS01E to SMC has a clinically signifi-
cant benefit.
Superiority: the trial is designed to compare the two 
interventions combined with either used alone. The study 
is powered to (1) assess the statistical evidence against the 
null hypothesis of no difference between the combined 
group and either used alone, and (2) estimate the effi-
cacy of the combined group with a relatively high degree 
of precision. This latter aspect is important because it is 
necessary to show that adding RTS,S/AS01E to SMC has 
clinically significant benefit.
Based on the incidence of events observed in the trial 
after two years of follow- up, with approximately 2000 indi-
viduals in each arm, if the efficacy is 30% or more, there 
is very high power over the three years of the study (close 
to 100%) to reject the null hypothesis of no difference 
between the treatment groups. There will be 90% power 
for the lower limit of the CI to exclude 15%, that is, to 
establish that the protection from the combined group is 
at least 15% better than SMC or vaccination alone.
Non- inferiority: SMC for 4 months of the year has an 
efficacy, assuming receipt of all 4 monthly cycles, of about 
85%. If, without intervention, the peak 4 months would 
account for 60% of annual cases (with the other 40% 
falling during the other months), this equates to an effi-
cacy over 12 months of at least 50%. The non- inferiority 
margin is the largest reduction in this efficacy that we 
would be willing to accept, or would consider unim-
portant, if RTS,S were to replace SMC. A reduction in 
efficacy from 50% to 40% translates to a 20% greater inci-
dence in the RTS,S- alone arm compared with the SMC- 
alone arm. The analysis plan will specify a margin of 20%, 
this takes into account the potential advantages of RTS,S 
over SMC in terms of ease of delivery and hence the like-
lihood of being able to sustain high levels of coverage. 
The trial has 80% power to exclude, at the 2.5% signifi-
cance level, a relative difference in the incidence of clin-
ical episodes of malaria of 20% over the three year study 
period between the RTS,S/AS01E and SMC alone groups, 
if these two interventions were equally effective.
For the analysis of the serological response to RTS,S/
AS01E, comparisons will be made between mean anti- CSP 
antibody titres before and after the primary series of 
vaccination and before and after each subsequent booster 
dose. Based on the SD in antibody titres observed in chil-
dren enrolled in the RTS,S/AS01E phase 2 and phase 3 
trials, inclusion of around 160 individuals in each group 
(prevaccination and postvaccination) will give approx-
imately 80% power to detect a difference of 25%–30% 
in mean titre between children who receive RTS,S/AS01E 
with or without co- administration of SMC.
Follow-up and measurement of outcomes
Passive surveillance for cases of uncomplicated and 
severe malaria: project staff based in the study hospitals 
and health centres that serve the study communities 
identify and document all cases of malaria who present 
to these health facilities. Community health workers refer 
all suspected malaria cases to study health facilities. Blood 
films and filter paper strips are obtained from all these 
cases for subsequent confirmation of the diagnosis by 
microscopy.
Active surveillance for malaria: each week, 24 randomly 
selected children (8 from each arm of the study) in each 
country are visited at home, their temperature measured 
and a blood film collected. Any child who is febrile or 
who has other features suggestive of malaria is tested with 
an RDT and treated with a full course of an artemisinin 
combination therapy (ACT) if positive.
Prevalence of malaria parasitaemia and anaemia: 
a survey of all study children is undertaken at least 
one month after the last round of SMC administration 
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at the end of each malaria transmission season. During 
these surveys, anthropometric measurements are taken 
and a finger prick blood sample is collected for preparing 
blood slides and blood spots. Children who are febrile are 
tested with an RDT and treated with an ACT if positive.
Malaria endemicity in the study area: a survey of school-
children aged 6–12 years resident in the same areas as the 
study children is conducted at the end of each malaria 
transmission season. Two hundred randomly selected 
schoolchildren per country (total 400) aged 6–12 years 
who are well and have not received SMC are tested for 
malaria by microscopy.
Measurement of the immune response to vaccination: 
blood samples (2 mL) have been collected from approxi-
mately 160 children in each of the groups (80 per country) 
who received RTS,S/AS01E prior to administering the 
first dose of vaccine and one month after the third dose 
of the primary series of vaccination had been given. In 
years 2 and 3, samples have been collected one month 
before and after administration of the fourth and fifth 
doses of vaccine for measurement of anti- CSP antibodies.
Measurement of resistance to the antimalarial drugs 
used for SMC: dried blood spots from a randomly group 
of children who have malaria parasitaemia detected by 
microscopy at the last cross- sectional survey will be used 
for analysis of molecular markers of resistance to SP and 
AQ.
SAEs: project staff based at the study hospitals have 
been provided with additional training on the recogni-
tion of meningitis, cerebral malaria and immune defi-
ciency diseases, and standard operating procedures have 
been developed for management of children suspected 
of having one of these conditions. Definitions for menin-
gitis and cerebral malaria developed by WHO for use in 
the pilot RTS,S/AS01E implementation trials are being 
applied. All deaths occurring outside the health facili-
ties are assessed by verbal autopsy using the WHO 2016 
Verbal Autopsy Questionnaire.13 Any SAEs that are (a) 
considered by the investigators likely to be linked to the 
administration of a study vaccine or study drug or (b) are 
suspected cases of meningitis or cerebral malaria or (c) 
are fatal or life threatening are thoroughly investigated 
and reported to GSK and to the Data Safety Monitoring 
Board (DSMB) within 72 hours of their detection. All 
SAEs, whether considered related to the study inter-
ventions or not, are tabulated in a blinded fashion and 
provided to the DSMB and to GSK quarterly.
Laboratory methods
Detection of malaria: a histidine- rich protein 2 (HRP2) 
based RDT is used for the initial diagnosis of malaria and 
to guide treatment. Blood films collected at the same 
time are read subsequently by two readers following the 
guidelines developed for the phase 3 RTS,S/AS01E trial.
14 
Slides which are judged to be discordant for either posi-
tivity or parasite density are read by a third reader, and 
the discrepancy was resolved following the algorithm 
used in the above study.14
Measurement of haemoglobin concentration: haemo-
globin concentration is measured colourimetrically using 
a HemoCue colorimeter (HemoCue AB, Angelholm, 
Sweden).
Detection of markers of resistance to SP and AQ: para-
site DNA will be extracted from dried blood spots and 
nested PCR reactions will be used to detect the presence 
of mutations in the dhfr and dhps genes associated with 
resistance to pyrimethamine and sulphadoxine, respec-
tively, and the pfcrt and pfmdr mutations associated with 
resistance to AQ. PCR- Restriction Fragment Length Poly-
morphism (RFLP) will be used to detect the N511, C59R, 
S108N and I164L mutations in the dhfr gene, the A437G 
and K540E mutations in the dhps gene, the N86Y muta-
tion in the pfmdr1 gene and the K76T mutation in the 
pfcrt gene.
Measurement of anti- CSP concentration: antibodies 
to CSP will be measured by a standardised ELISA at the 
University of Ghent laboratory using a method applied in 
previous trials of RTS,S/AS01E.
Detection of polymorphisms in the csp gene: sequencing 
of the C- terminal region of the CSP protein will be under-
taken using methods described previously for detecting 
polymorphisms in this region of the csp gene to look for 
the selection effect of RTS,S/AS01E vaccine on malaria 
parasites.15
Investigation of suspected cases of meningitis: the 
aetiology of cases of meningitis is determined by micro-
scopical examination of cerebrospinal fluid samples for 
bacteria and white blood cells at the district hospital and 
then by subsequent PCR testing at a reference laboratory.
Data management
Data are collected using electronic case record forms 
(eCRF) developed using Open Data Kit software. Tablet 
computers loaded with eCRFs are available at all study 
health centres that provide treatment. This system 
is based on electronic transfer of the CRFs from the 
research sites. Automatic checks are performed on 
clinical and laboratory forms to ensure that they are 
complete and contain valid responses prior to transfer-
ring data. eCRFs will be deposited with the study data 
on the LSHTM Data Compass System (http:// data-
compass. lshtm. ac. uk). All personal identifiers will be 
removed from the study database before archiving. The 
data will be assigned a digital object identifier. Twelve 
months after completing the analysis, the data will be 
made available in the London School of Hygiene and 
Tropical Medicine (LSHTM) data depository. A data 
access group will review requests to share archived data.
Analysis plan
The primary analysis will be by modified intention to 
treat (mITT). The mITT population will include all 
children who were screened and who received the 
first dose of RTS,S/AS01E or control vaccine, irrespec-
tive of the number of doses of subsequent vaccines or 
SMC/SMC placebo received. The primary endpoint of 
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the trial is the incidence of all episodes of blood slide 
confirmed clinical malaria over the study period and 
this will be evaluated using Cox regression models with 
a robust SE to account for clustering of episodes within 
individuals (ie, the Andersen- Gill extension of the Cox 
model). Hypothesis testing will follow the closed testing 
procedure, whereby there is initially a test of the null 
hypothesis that the incidence in the three groups is the 
same. If this is rejected at the 5% level, pairwise compar-
isons will also be done using a 5% significance level. 
Pairwise comparisons can be considered statistically 
significant only if the overall null hypothesis is rejected. 
This preserves the overall type I error rate at 5%. There 
were no formal interim analyses planned or conducted.
The primary analysis will be based on data for both 
sites combined, with site as a stratification factor, but 
site- specific analyses will also be undertaken. A test of 
interaction will be used to determine if there is any 
evidence that efficacy of RTS,S varies between the two 
trial sites. An analysis will also be undertaken to assess 
efficacy of the booster dose of the vaccine each year.
The proportion of children in each group who expe-
rience at least one episode of malaria will be compared 
as a secondary outcome using Kaplan- Meier estimates 
of the risk. Evidence for provision of complete protec-
tion through the combination of SMC and vaccination 
each year will be explored using published methods.16 17 
For the comparison of RTS,S/AS01E plus SMC versus 
the other two study groups, two- sided 95% CIs for the 
HR will be calculated. For the non- inferiority compar-
ison of RTS,S/AS01E to SMC, two- sided 90%, 95% and 
99% CIs for the rate ratio will be calculated, to indicate 
the degree of confidence with which the margin of 1.20 
(a relative increase of 20%) can be excluded.
An analysis plan will be prepared, for approval by the 
DSMB before the study code is broken. Primary analyses 
will be by mITT. ATP analyses will also be undertaken. 
Efforts would be made during the trial to ensure high 
levels of adherence to minimise differences between 
ITT and ATP populations. All children who received 
the first dose of vaccine will be included in the intention 
to treat analysis. (Children who did not attend for the 
first vaccine dose were withdrawn from the study.) Chil-
dren who received all scheduled doses of SMC, or treat-
ment for a clinical episode of malaria at a time when 
SMC would have been given, and all scheduled doses 
of vaccine, will be included in the per protocol analysis 
for each year of the study. Additional subanalyses will 
include analysis by age, gender, bed net use during the 
transmission season and socioeconomic status.
Trial management
The LSHTM is the main sponsor for the trial. Delegated 
responsibilities are assigned locally. The LSHTM holds 
Public Liability (‘negligent harm’) and Clinical Trial (‘non- 
negligent harm’) insurance policies which apply to this trial. 
An independent trial steering committee provides scien-
tific oversight and has approved the protocol. The steering 
committee holds teleconferencing or face- to- face meeting 
annually to monitor progress and advise on the scientific 
content of the study. The quality of data and the good clin-
ical practice (GCP) standards of the trial are monitored by 
an independent, experienced GCP monitor.
ETHICS AND DISSEMINATION
Ethics
Inclusion in the trial of an RTS,S/AS01E alone group is 
justified, even though SMC is a recommended policy, on 
the grounds that RTS,S/AS01E could provide some added 
protection outside the main transmission season when SMC 
is not being given and that it may be easier to administer 
than SMC. Individual, written, informed consent has been 
obtained from the family or legally recognised guardian of 
each child entered into the trial. Conduct of the trial does 
not impose any additional costs on the local health services. 
The project contributes to the costs of routine clinical care 
of study subjects during the trial and to strengthening of clin-
ical care at the district hospitals in the study areas.
Ethical approval has been obtained from the Ethics 
Committee of LSHTM, the Health Research Ethics 
Committee of Burkina Faso, the Institutional Ethics 
Committee of IRSS in Burkina Faso and the Ethics Committee 
of the Faculty of Medicine, Pharmacy and Dentistry, Univer-
sity of Bamako (protocol V.2; dated 9 December 2016). The 
trial has also been approved by the regulatory authorities in 
Burkina Faso and Mali. An independent DSMB monitors 
regularly the safety of children in the trial, especially those 
in the RTS,S/AS01E alone group who are not receiving SMC, 
which is a standard of care. In February 2018, the board 
reviewed unblinded data on the incidence of SAEs and SAEs 
due to malaria in each study group, and gave permission for 
the trial to proceed for a further year retaining all three study 
arms.
The trial adheres to the principles outlined in the Inter-
national Conference on Harmonisation GCP guidelines, 
protocol and all applicable local regulations. The trial is 
registered on  clinicaltrials. gov (https://www. clinicaltrials. 
gov/ ct2/ show/ NCT03143218? term= NCT03143218& rank= 
1).
Dissemination plans
Results from the trial will be discussed with the study 
communities at the end of the study, presented at national 
and international conferences and in peer- reviewed, open 
access journals. Trial results will be shared with the WHO’s 
technical expert groups and Malaria Policy Advisory Group. 
Strong links have been established already with the MoHs, 
NMCPs and EPI programmes in Burkina Faso and Mali. 
The trial team has also established good links with many 
other organisations involved in the delivery of SMC trials, 
including the SMC ACCESS programme and with the WHO 
staff responsible for conducting the RTS,S/AS01E implemen-
tation studies. Thus, if it is found that RTS,S/AS01E vaccine is 
a useful replacement or an addition to SMC regimens, routes 
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have already been established through which this knowledge 
could be disseminated rapidly.
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